Therapeutic strategies targeting brain tumor stem cells

Brain and Nerve

Volumn 61, Issue 7, 2009, Pages 799-803

  Toda, Masahiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antigen; Cancer stem cell; Glioma; Immunotherapy; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER STEM CELL; CULTURE TECHNIQUE; CYTOLOGY; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; NEURAL STEM CELL; PURIFICATION; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASTIC STEM CELLS; RECEPTORS, NOTCH;

EID: 67849112958     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008
2. Vescovi AL, Galli R, Reynolds BA: Brain tumour stem cells. Nat Rev Cancer 6: 425-436, 2006
3. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005 (Pubitemid 40488633)
4. Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, et al: Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54: 850-860, 2006 (Pubitemid 44671990)
5. Kang MK, Kang SK: Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 16: 837-847, 2007
6. Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, et al: Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10: 719-728, 1999 (Pubitemid 30015673)
7. Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, et al: Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 9: 650-656, 2003 (Pubitemid 36182597)
8. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al: Identification of cells initiating human melanomas. Nature 451: 345-349, 2008
9. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, et al: Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524-2533, 2007 (Pubitemid 47582744)
10. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A: HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self- renewal, and tumorigenicity. Curr Biol 17: 165-172, 2007 (Pubitemid 46107823)
11. Fan X, Matsui W, Khaki L, Stearns D, Chun J, et al: Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66: 7445-7452, 2006 (Pubitemid 44289197)
12. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, et al: Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour- initiating cells. Nature 444: 761-765, 2006 (Pubitemid 44949605)
13. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82, 2007 (Pubitemid 46054518)
14. Toda M: Immuno-viral therapy as a new approach for the treatment of brain tumors. Drug News Perspect 16: 223-229, 2003 (Pubitemid 37039404)
15. Becher B, Prat A, Antel JP: Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29: 293-304, 2000 (Pubitemid 30121420)
16. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842-847, 2001 (Pubitemid 32175145)
17. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287, 1999
18. Kawakami Y, Rosenberg SA: Human tumor antigens recognized by T-cells. Immunol Res 16: 313-339, 1997 (Pubitemid 28026418)
19. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, et al: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108: 963-971, 2008 (Pubitemid 351656845)
20. Yamanaka R: Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med 14: 228-235, 2008
21. Iizuka Y, Kojima H, Kobata T, Kawase T, Kawakami Y, et al: Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. Int J Cancer 118: 942-949, 2006 (Pubitemid 43157669)
22. Ohashi Y, Ueda M, Kawase T, Kawakami Y, Toda M: Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning. Oncogene 23: 7772-7779, 2004 (Pubitemid 39457027)
23. Ueda R, Yoshida K, Kawase T, Kawakami Y, Toda M: Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J Cancer 120: 1704-1711, 2007 (Pubitemid 46399357)
24. Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, et al: Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene 23: 1420-1427, 2004 (Pubitemid 38406837)
25. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, et al: Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 11: 637-653, 2000 (Pubitemid 30134307)
26. Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, et al: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2: 164-167, 1995